Nanomi joins consortium to address chronic kidney disease

24-Jun-2009 - Netherlands

Nanomi, provider of microsphere-based drug delivery technologies to the pharmaceutical industry, announced that it joined a consortium for the development of a therapy to prevent chronic kidney disease.

The consortium partners, four companies, two universities and two academic hospitals, will jointly develop a therapy where biodegradable polymer microspheres, loaded with anti-inflammatory and anti-fibrotic compounds, will be implanted in the kidney. The impanted microspheres will provide a local drug depot with a sustained drug release profile, maximizing the intended therapeutic effects and minimizing systemic side-effects. The therapy aims to restore the kidney function, thus reducing the need for transplantations.

The Dutch Top Institute BioMedical Materials (BMM) — a public-private partnership dedicated to research and development of novel biomedical materials and their therapeutic application — has decided to fund this "top quality innovative R&D project" with approximately 4.2 million Euro.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance